Buy AbbVie: Immunology Cash Flow Backstops an Aggressive Oncology Growth Plan
AbbVie is using steady immunology cash flow and a growing oncology franchise to offset legacy biologic declines. The balance sheet and $21.5B in free cash flow support dividends and M&A or commercialization spend; combine that with encouraging long-term venetoclax data and a ramping blood-cancer portfolio and you get asymmetric upside to $245 over …